CNSI Cambridge Neuroscience Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CNSI Cambridge Neuroscience

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Peter R Smith who started this subject	3/1/2001 5:24:00 AM
From: nigel bates	Read Replies (1) of 675

New CeNeS Drug Aims To Combat Substance Abuse 1/3/2001 Drugs Development And Delivery Vendor Obtains Investigational New Drug (IND) Application Approval; initial Trial Focuses on Alcohol Abuse Aimed at cutting dependence on the gamut of substances such as alcohol and cocaine, and the associated mounting cost of substance-induced crimes and accidents, drug developer CeNeS Pharmaceuticals plc ("CeNeS") today announces that it has received approval to move its CEE 03-310 drug project into clinical trials. A placebo controlled Phase II study will be carried out at Yale University, USA. As part of a broad development programme, the initial clinical trial will measure the extent that CeNeS' novel CEE 03-310 drug reduces problem drinkers' craving for alcohol and its consumption.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next